PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 208 participants.
Also called NCT03808376
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase
- Not applicable
- Enrolled
- 208 participants
- Sponsor
- Registry
-
NCT03808376
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03808376. Allocation not applicable; no masking; primary purpose diagnostic. Start 2018-12-27 (actual); primary completion 2020-05-08 (actual). Results posted on 2024-08-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- PROMISE Study: An Evaluation of an Implantable Continuous Glucose Sensor up to 180 Days
- Acronym
- PROMISE
- Condition
- Diabetes Mellitus
- Condition
- Diabetes Mellitus, Type 1
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Device)
- Continuous Glucose Monitoring System
- Lead sponsor
- Senseonics, Inc.
Record details
- Record id
cardio:ct-nct03808376- Content hash
bc2dc90ad87e5f4556986379e4cab39432062e6b5c32b8b032399cf3095951a2